IN THE CLAIMS

Please amend the claims as follows.

1. (Currently amended) A composition comprising immunosuppressants, cyclosporins, FK506, or rapamycin and at least one bioactive peptide comprising the high-affinity binding/anti-lymphoproliferative site of interferons α, β, ω, τ, or recombinant proteins carrying one or more of the sequences**, wherein said bioactive peptide comprises one or more of the sequences of SEQ ID NO: 1 or a variant thereof that is SEQ ID NO: 2, such that at up to three amino acids of SEQ ID NO: 1 are substituted,** ~~comprising the structures of said bioactive peptides~~ for the aim of amplification of immunosuppressants' activities to decrease their therapeutic dose, and as the consequence to avoid their undesirable side effects during organ and tissue transplantation.

2-3. (cancelled)

4. (previously presented) The composition according to Claim 5 wherein the bioactive peptide is genetically or chemically modified or genetically or chemically or physically bound to a small-molecular or macromolecular substance increase the stability

of the bioactive peptide in physiological conditions or for regulating the bioavailability of the bioactive peptide.

5. (Currently Amended) The composition according to claim 1, comprising at least one cyclosporin, rapamycin or FK506 and a bioactive peptide consisting of the amino acid sequence of **SEQ ID NO:1** ~~SEQ ID NO. 1~~ or being a variant of **SEQ ID NO:1** ~~SEQ. ID NO. 1~~ that is **SEQ ID NO:2** ~~SEQ. ID. NO. 2~~ such that zero to three amino acids of **SEQ ID NO:1** ~~SEQ ID NO. 1~~ are substituted.

6-18. (cancelled)

19. (Currently Amended) A composition comprising immunosuppressants, cyclosporins, FK506, or rapamycin and at least one bioactive peptide consisting of **SEQ ID NO:1** ~~SEQ ID NO. 1~~ or being a variant of **SEQ ID NO:1** ~~SEQ. ID NO. 1~~ that is **SEQ ID NO:2** ~~SEQ. ID. NO. 2~~ such that zero to three amino acids of **SEQ ID NO:1** ~~SEQ ID NO. 1~~ are substituted, or recombinant proteins carrying one or more of said bioactive peptide for the aim of amplification of immunosuppressants' activities to decrease their therapeutic dose, and as the consequence to avoid their undesirable side effects

during organ and tissue transplantation or during treatment of diseases wherein cyclosporins, FK506 or rapamycin can be exploited.